Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs

Journal of Viral Hepatitis

Volumn 19, Issue 3, 2012, Pages 205-212

  Chotiyaputta, W ^a   Hongthanakorn, C ^a   Oberhelman, K ^a   Fontana, R J ^a   Licari, T ^a   Lok, A S F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

antiviral resistance; antiviral therapy; HBV DNA; hepatitis B treatment

Indexed keywords

ADEFOVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; ASIAN; CLINICAL PRACTICE; FEMALE; GENOTYPE; HEALTH CARE PERSONNEL; HEALTH SURVEY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POSTGRADUATE EDUCATION; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; QUESTIONNAIRE; TREATMENT DURATION;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NUCLEOSIDES; QUESTIONNAIRES; YOUNG ADULT;

EID: 84857369276     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01494.x     Document Type: Article

References (33)

1. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010. (Pubitemid 43357804)
2. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020. (Pubitemid 43357805)
3. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588. (Pubitemid 350294224)
4. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455.
5. Westland CE, Yang H, Delaney IV, WE, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38: 96-103. (Pubitemid 36775800)
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807. (Pubitemid 36245756)
7. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816. (Pubitemid 36245757)
8. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F,. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12: 239-245. (Pubitemid 47400613)
9. Bouchard MH, Dragomir A, Blais L, Berard A, Pilon D, Perreault S,. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007; 63: 698-708. (Pubitemid 46753568)
10. Dragomir A, Cote R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care 2010; 48: 418-425.
11. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860. (Pubitemid 28135961)
12. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30. (Pubitemid 30432540)
13. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G,. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146: 564-573. (Pubitemid 351650537)
14. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191: 339-347. (Pubitemid 40139758)
15. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40: 158-163. (Pubitemid 40053474)
16. Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS,. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011; 54: 12-18.
17. Osterberg L, Blaschke T,. Adherence to medication. N Engl J Med 2005; 353: 487-497. (Pubitemid 41127293)
18. Walsh JC, Mandalia S, Gazzard BG,. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS 2002; 16: 269-277. (Pubitemid 34118574)
19. Lu M, Safren SA, Skolnik PR, et al. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav 2008; 12: 86-94. (Pubitemid 351143454)
20. Degertekin B, Hussain M, Tan J, Oberhelman K, Lok AS,. Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol 2009; 50: 42-48.
21. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134: 968-977. (Pubitemid 32466236)
22. Amico KR, Konkle-Parker DJ, Cornman DH, et al. Reasons for ART non-adherence in the Deep South: adherence needs of a sample of HIV-positive patients in Mississippi. AIDS Care 2007; 19: 1210-1218. (Pubitemid 350249254)
23. Jackson JE, Doescher MP, Saver BG, Fishman P,. Prescription drug coverage, health, and medication acquisition among seniors with one or more chronic conditions. Med Care 2004; 42: 1056-1065. (Pubitemid 39472112)
24. Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG,. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 2009; 119: 390-397.
25. Maciejewski ML, Bryson CL, Perkins M, et al. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. Am J Manag Care 2010; 16: e20-e34.
26. Donnelly LA, Doney AS, Morris AD, Palmer CN, Donnan PT,. Long-term adherence to statin treatment in diabetes. Diabet Med 2008; 25: 850-855.
27. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RM,. Long term persistence with statin treatment in daily medical practice. Heart 2004; 90: 1065-1066. (Pubitemid 39127934)
28. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD,. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160: 31-37. (Pubitemid 29054224)
29. Marentette MA, Gerth WC, Billings DK, Zarnke KB,. Antihypertensive persistence and drug class. Can J Cardiol 2002; 18: 649-656.
30. Kane SV, Cohen RD, Aikens JE, Hanauer SB,. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-2933. (Pubitemid 32959535)
31. Parienti JJ, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS ONE 2008; 3: e2783.
32. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38: 1311-1316. (Pubitemid 38608576)
33. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21: 965-971. (Pubitemid 46684328)